Explore GEN family of websites, social media experiences, blogs and more.

Unleashing ideas.
Strengthening startups.

Back to search results
    Date submitted
  • 13-Feb-2014

OrthoGraft, LLC


OrthoGraft is developing a biomaterial for bone regeneration consisting of collagen, hydroxyapatite, and natural occurring designer proteins that mediate biomineralization. The result is a self-assembled nano-orthobiologic that promises to limit the occurrences of non-unions in the spine and extremities through a novel stimulatory mechanism known as osteoinductive nanoarchitecture. Our FDA regulatory timeline projects penetration into the $4 billion bone substitute market 3 years following our seed funding round. We are currently raising a seed fund of $250k for our first animal trials.

Additional Questions

Investor questions have not yet been answered for this business